

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America	
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,  
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),  
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002

NEWS HOURS      STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

---

NEWS LOGIN      Welcome Banner and News Items

**NEWS PHONE** Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:21:20 ON 04 OCT 2002

=> file reg  
COST IN U.S. DOLLARS  
  
FULL ESTIMATED COST

SINCE FILE ENTRY 0.21	TOTAL SESSION 0.21
-----------------------------	--------------------------

FILE 'REGISTRY' ENTERED AT 14:21:36 ON 04 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 OCT 2002 HIGHEST RN 459123-02-5  
DICTIONARY FILE UPDATES: 3 OCT 2002 HIGHEST RN 459123-02-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See **HELP CROSSOVER** for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=>  
L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR  
20 C M2  
Page 1-A




Page 1-B


0 32 S 33




Page 1-D



Page 1-E




Page 1-F



Page 2-B

Page 2-C



Page 2-D

Page 2-E

Page 2-F

VAR G1=29/30  
VAR G2=32/33  
REP G19=(0-1) 20-19 20-23  
REP G20=(0-1) 10-9 10-11  
VPA 7-4/5/6 S

NODE ATTRIBUTES:

HCOUNT	IS M2	AT	9
HCOUNT	IS M2	AT	10
HCOUNT	IS M2	AT	19
HCOUNT	IS M2	AT	20
HCOUNT	IS M1	AT	23
HCOUNT	IS M1	AT	25
HCOUNT	IS M3	AT	29
HCOUNT	IS M2	AT	30
HCOUNT	IS E3	AT	31
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS C	AT	7
NSPEC	IS C	AT	8
NSPEC	IS C	AT	9
NSPEC	IS C	AT	10
NSPEC	IS C	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS C	AT	18
NSPEC	IS C	AT	19
NSPEC	IS C	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS R	AT	25
NSPEC	IS C	AT	26
NSPEC	IS C	AT	27
NSPEC	IS C	AT	28
DEFAULT	MLEVEL	IS	ATOM
MLEVEL	IS	CLASS	AT 7 9 10 19 20 29 30 31 32 33
DEFAULT	ECLEVEL	IS	LIMITED

GRAPH ATTRIBUTES:

RSPEC I  
NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

=> **s 11**  
SAMPLE SEARCH INITIATED 14:22:37 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 11 TO 389  
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> **s 11 full**  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 139.90 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:**y**  
FULL SEARCH INITIATED 14:22:50 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 310 TO ITERATE

100.0% PROCESSED 310 ITERATIONS 48 ANSWERS  
SEARCH TIME: 00.00.07

L3 48 SEA SSS FUL L1

=> **file hcplus**  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
140.66 140.87

FILE 'HCPLUS' ENTERED AT 14:23:03 ON 04 OCT 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Oct 2002 VOL 137 ISS 15  
FILE LAST UPDATED: 3 Oct 2002 (20021003/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> **s 13**  
L4 490 L3

=> s 14 and hydra?

352752 HYDRA?

L5 14 L4 AND HYDRA?


=> d 15, ibib abs fhitstr, 1-14

L5 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full  Citing  
 Text  References

ACCESSION NUMBER: 2002:637641 HCAPLUS  
 DOCUMENT NUMBER: 137:169309  
 TITLE: Preparation of substituted aminobenzene derivatives as glucocorticoid receptor modulators  
 INVENTOR(S): Link, James T.; Sorensen, Bryan K.; Patel, Jyoti R.; Arendsen, David L.; Li, Gaoquan  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: PCT Int. Appl., 272 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064550	A1	20020822	WO 2002-US4501	20020212
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
PRIORITY APPLN. INFO.:			US 2001-783636	A 20010214
OTHER SOURCE(S):			MARPAT 137:169309	
GI				



AB Gen, hydroxyalkyl, substituted amine; R4 is substituted aminobenzenes I were prep'd. and are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal, wherein R1-R3 are each independently hydrogen, alkoxy carbonyl, alkoxy, alkoxyalkyl, alkyl, alkyl carbonyl, carboxy, halogen, hydroxyalkyl, substituted amine; R4 is hydrogen, alkenyl, alkoxy, alkoxyalkenyl, alkoxyalkoxy, alkoxyalkyl, alkoxyalkynyl, alkoxy carbonyl, alkoxy carbonyl alkoxyl, alkoxy carbonyl alkyl, alkoxy carbonyl alkyl, alkoxy carbonyl alkynyl, alkoxy carbonyl alkynyl, alkyl, alkyl carbonyl, alkyl carbonyl alkyl, alkyl carbonyl alkynyl, alkyl carbonyl alkoxyl, alkyl carbonyl alkynyl, alkynyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, haloalkoxy, haloalkyl, haloalkenyl, haloalkynyl, halogen, hydroxyalkyl, substituted amine; R5 is hydrogen, alkyl; R6 is hydrogen, alkoxy carbonyl, alkoxy sulfonyl, alkyl, alkyl carbonyl, alkyl sulfonyl, aryl alkoxycarbonyl, aryl alkyl carbonyl, aryl alkyl sulfonyl, aryl carbonyl, aryl sulfonyl, cycloalkyl carbonyl, cycloalkyl sulfonyl, cycloalkyl alkyl sulfonyl, heterocycle carbonyl, heterocycle alkyl carbonyl, heterocycle sulfonyl, heterocycle alkyl sulfonyl, amide, aminosulfonyl; X and Y are independently heteroatom-contg. hydrocarbon. Thus, N-[3-(dibenzylamino)-2-methylphenyl]ethanesulfonamide was prep'd. as glucocorticoid receptor

modulator. A method of treating symptoms related to type II diabetes wherein said symptoms are selected from the group consisting of hyperglycemia, hyperinsulinemia, inadequate, glucose clearance, obesity, hypertension and high glucocorticoid levels in a mammal comprising administering a therapeutically effective amt. of a compd. of title compds. A method of treating diseases assocd. with an excess or deficiency of glucocorticoids, said diseases selected from the group consisting of diabetes, obesity, Syndrome X, Cushing's Syndrome, Addison's disease, inflammatory diseases such as asthma, rhinitis and arthritis, allergy, autoimmune disease, immunodeficiency, anorexia, cachexia, bone loss or bone frailty, and wound healing comprising administering a therapeutically effective amt. of a compd. of title compds.


IT 122320-73-4, Rosiglitazone

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of substituted aminobenzene derivs. as glucocorticoid receptor modulators)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:

2001:904164 HCAPLUS

DOCUMENT NUMBER:

136:20065

TITLE:


5-[(4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical

INVENTOR(S):

Craig, Andrew Simon; Ho, Tim Chien Ting; Millan, Michael John

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK  
SOURCE: PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094343	A1	20011213	WO 2001-GB2545	20010608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2000-14005	A 20000608
GT				



AB The title compd. (I·HI) is prep'd. by refluxing I with HI in various solvents (2-propanol, THF, toluene, etc.). The hydriodide **hydrate** is also prep'd. and x-ray powder diffraction patterns are provided. I·HI is indicated to be useful in the treatment and/or prophylaxis of diabetes mellitus and certain of its complications.


IT 122320-73-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(conversion to hydriodide)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full  Citing  
 Text  References

ACCESSION NUMBER: 2001:816444 HCAPLUS  
 DOCUMENT NUMBER: 135:352829  
 TITLE: Combination therapeutic compositions containing benzene compounds  
 INVENTOR(S): Jaen, Juan C.; Chen, Jin-Long  
 PATENT ASSIGNEE(S): Tularik Inc., USA  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082916	A2	20011108	WO 2001-US14393	20010502
WO 2001082916	A3	20020704		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002037928	A1	20020328	US 2001-847887	20010502


PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

US 2000-201613P P 20000503

MARPAT 135:352829

GI



**AB** The present invention provides pharmaceutical compns. and methods for the treatment of diabetes mellitus using combination therapy. The compns. relate to a benzene compd. and an antidiabetic agent such as sulfonylureas, biguanides, glitazones,  $\alpha$ -glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of benzene compd. with antidiabetic agent where the two components are delivered in a simultaneous manner, where the benzene compd. is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the benzene compd. For example, the benzene compd. (I) was synthesized using a 5-amino-2-(3-chloro-5-pyridyloxy)benzonitrile (0.457 g) in methylene chloride to which was added 2,4-dichlorobenzenesulfonyl chloride (0.456 g), followed by pyridine (150  $\mu$ L). The reaction progress was monitored by TLC, and upon completion the solvent was removed under vacuum. The resulting residue was partitioned between methylene chloride and water. The org. layer was drawn off and concd. The residue was triturated with ether to provide 0.447 g of I as a white solid, m.p. 154-156°.

**IT** 122320-73-4, Rosiglitazone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(benzene compds. in combination therapy for diabetes and diabetes-related disorders)


**RN** 122320-73-4 HCPLUS

**CN** 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2001:780683 HCAPLUS  
 DOCUMENT NUMBER: 135:335156  
 TITLE: Modified-release formulations containing a hypnotic agent  
 INVENTOR(S): Platteeuw, Johannes Jan; Van Den Heuvel, Dennie Johan Marijn; Van Dalen, Frans; Lemmens, Jacques Maria  
 PATENT ASSIGNEE(S): Synthon B.V., Neth.  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078725	A2	20011025	WO 2001-NL299	20010412
WO 2001078725	A3	20011220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-196939P P 20000413

AB Hypnotic pharmaceutical compns. are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably spherical and exhibit a dissoln. profile that includes 60% of the hypnotic agent being released from the pellet not earlier than 5 min from the start of a specified in vitro dissoln. test. Although the modified release profile can include 50% of the hypnotic agent being released not earlier than 15 min after the start of the dissoln. test, the pellet preferably does not contain a release rate controlling excipient or coating. Instead, microcryst. cellulose and the active constitute the majority of the pellet, e.g. 90 or more. Spherical pellets are also made by a convenient method that is applicable to any pharmaceutically active agent. Microcryst. cellulose 1703, zolpidem hydrochloride **hydrate** 189.2 g, and water 1892 mL were mixed and stirred for 15 min. Water was then removed and the resulted pellets were dried and fractionated by sieving.


IT 122320-73-4, Rosiglitazone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified-release formulations contg. hypnotic agent)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[(4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl)methyl]-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 5 OF 14 HCPLUS COPYRIGHT 2002 ACS

 Full Text     Citing References

ACCESSION NUMBER: 2001:693320 HCPLUS  
 DOCUMENT NUMBER: 135:247196  
 TITLE: Preparation of non-hygroscopic hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione  
 INVENTOR(S): Craig, Andrew Simon  
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK  
 SOURCE: PCT Int. Appl., 19 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068646	A1	20010920	WO 2001-GB1131	20010314
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>PRIORITY APPLN. INFO.:</u>			GB 2000-6133	A 20000314
AB	A substantially non-hydrated and non-hygroscopic or slightly hygroscopic hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-			

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (I); a pharmaceutical compn. contg. such a compd., a process of prepg. such a compd. and the use of such a compd. in medicine is disclosed. I was prepd. by the reaction of HCl with the base, m.p. = 167-170. I was non-hygroscopic.


IT 302543-62-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of non-hygroscopic hydrochloride salts of  
pyridylaminoethoxybenzyl thiazolidinedione)


RN 302543-62-0 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met hyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



# HCl

REFERENCE COUNT:

2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 14 HCPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:

2001:584706 HCPLUS

DOCUMENT NUMBER:

135:352600

TITLE:

Peroxisome proliferator-activated receptor  
subtype-specific regulation of hepatic and peripheral  
gene expression in the Zucker diabetic fatty rat  
Dana, Sharon L.; Hoener, Patricia A.; Bilakovics,  
James M.; Crombie, Diane L.; Ogilvie, Kathleen M.;  
Kauffman, Raymond F.; Mukherjee, Ranjan; Paterniti,  
James R., Jr.

AUTHOR(S):

Department of Pharmacology, Ligand Pharmaceuticals,

CORPORATE SOURCE:

SOURCE: Inc., San Diego, CA, 92121, USA  
 Metabolism, Clinical and Experimental (2001), 50(8),  
 963-971  
 CODEN: METAAJ; ISSN: 0026-0495

PUBLISHER: W. B. Saunders Co.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Fibrates and thiazolidinediones are used clin. to treat hypertriglyceridemia and hyperglycemia, resp. Fibrates bind to the peroxisome proliferator-activated receptor (PPAR)- $\alpha$ , and thiazolidinediones are ligands of PPAR- $\gamma$ . These intracellular receptors form heterodimers with retinoid X receptor to modulate gene transcription. To elucidate the target genes regulated by these compds., we treated Zucker diabetic fatty rats (ZDF) for 15 days with a PPAR- $\alpha$ -specific compd., fenofibrate, a PPAR- $\gamma$ -specific ligand, rosiglitazone, and a PPAR- $\alpha$ -/ $\gamma$  coagonist, GW2331, and measured the levels of several mRNAs in liver by real-time polymerase chain reaction. All 3 compds. decreased serum glucose and triglyceride levels. Fenofibrate and GW2331 induced expression of acyl-CoA (CoA) oxidase and enoyl-CoA **hydratase** and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs. Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue. We identified a novel target in liver, mitogen-activated phosphokinase phosphatase 1, whose down-regulation by PPAR- $\alpha$  agonists may improve insulin sensitivity in that tissue by prolonging insulin responses. The results of these studies suggest that activation of PPAR- $\alpha$  as well as PPAR- $\gamma$  in therapy for type 2 diabetes will enhance glucose and triglyceride control by combining actions in hepatic and peripheral tissues.

IT 122320-73-4, Rosiglitazone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in Zucker diabetic fatty rat)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 14 HCPLUS COPYRIGHT 2002 ACS

Full  Citing  Text  References

ACCESSION NUMBER: 2001:338762 HCPLUS  
 DOCUMENT NUMBER: 134:362292  
 TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile  
 Farr, Spencer  
 INVENTOR(S):  
 PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA  
 SOURCE: PCT Int. Appl., 222 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 1999-165398P	P 19991105

US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

IT 122320-73-4, Rosiglitazone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)


RN 122320-73-4 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




Full Text Citing References

ACCESSION NUMBER: 2001:283949 HCAPLUS  
 DOCUMENT NUMBER: 134:311218  
 TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors  
 INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 221 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002
WO 2001027107	A3	20020124		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1224183	A2	20020724	EP 2000-968723	20001002
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
NO 2002001717	A	20020610	NO 2002-1717	20020411
			US 1999-158755P	P 19991012
			WO 2000-US27461	W 20001002

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 134:311218  
 GI



AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)ynyl, alk(enyl)ynyl, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butylidethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding  $\alpha$ -chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents,  $\beta$ -adrenergic agonists, hypolipidemic

agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

IT 122320-73-4, Rosiglitazone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals also contg.; synthesis and use of heterocyclic sodium/proton exchange inhibitors)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L5 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:861703 HCAPLUS  
 DOCUMENT NUMBER: 134:532  
 TITLE: Method and compositions relating to insulin resistance disorders  
 INVENTOR(S): Cawthorne, Michael; Sanchez, Jean-Charles  
 PATENT ASSIGNEE(S): Proteome Sciences PLC, UK  
 SOURCE: PCT Int. Appl., 188 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

WO 2000073330	A2	20001207	WO 2000-GB2110	20000601
WO 2000073330	A3	20010222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
GB 2350676 A1 20001206	GB 1999-12741	19990601
EP 1185862 A2 20020313	EP 2000-935377	20000601

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
---

PRIORITY APPLN. INFO.:	GB 1999-12741	A 19990601
	GB 2000-2973	A 20000209
	WO 2000-GB2110	W 20000601

AB Methods and compns. relating to insulin resistance are disclosed. Specifically, proteins that are differentially expressed in these conditions are identified. In one aspect, the invention provides a method of screening an agent to det. its usefulness in treating insulin resistance, based on establishing a paradigm in which at least one protein is differentially expressed in relevant tissue from, or representative of, subjects having differential levels of insulin sensitivity.

IT 122320-73-4, Brl 49653


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and compns. relating to insulin resistance disorders)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L5 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:756704 HCAPLUS  
 DOCUMENT NUMBER: 133:325652  
 TITLE: 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical  
 INVENTOR(S): Blackler, Paul David James; Craig, Andrew Simon; Giles, Robert Gordon; Sasse, Michael John  
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK  
 SOURCE: PCT Int. Appl., 15 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063206	A2	20001026	WO 2000-GB1527	20000419
WO 2000063206	A3	20010222		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173437	A2	20020123	EP 2000-920895	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009898	A	20020416	BR 2000-9898	20000419
NO 2001005105	A	20011219	NO 2001-5105	20011019
<u>PRIORITY APPLN. INFO.:</u>				
GB 1999-9075 A 19990420				
WO 2000-GB1527 W 20000419				

GI



AB 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate (I.HCl.H<sub>2</sub>O) is characterized in that it: (i) provides an IR spectrum contg. peaks at 3358, 2764, 1245, 833 and 760 cm<sup>-1</sup>; and/or (ii) provides an XRPD pattern contg. peaks at 15.0, 17.7, 23.0, 30.0 and 31.4 >2303082-83-9P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)


(5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical)

RN 303082-83-9 HCPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met

hyl]-, monohydrochloride, monohydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



\* HCl

\* H2O

L5 ANSWER 11 OF 14 HCPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:190914 HCPLUS

DOCUMENT NUMBER: 132:241947

TITLE: Compositions for treatment of glucose metabolism disorders

INVENTOR(S): Fine, Stuart; Kinsella, Kevin

PATENT ASSIGNEE(S): Akesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 2000015211</u>	A2	20000323	<u>WO 1999-US21377</u>	19990917
<u>WO 2000015211</u>	A3	20010329		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
<u>US 6376549</u>	B1	20020423	<u>US 1998-156102</u>	19980917
<u>AU 9960446</u>	A1	20000403	<u>AU 1999-60446</u>	19990917
<u>EP 1113804</u>	A2	20010711	<u>EP 1999-969024</u>	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				


PRIORITY APPLN. INFO.: US 1998-156102 A 19980917  
US 1999-126489P P 19990326  
WO 1999-US21377 W 19990917

AB Compns. and methods of using the same for the treatment of diabetes and other disorders of glucose metab. are provided. Compns. may include an anti-diabetic agent and 1 or more of a bioavailable source of chromium and vanadium. A supplement (detailed below) was administered daily to a female with Type 2 diabetes who was experiencing poor blood sugar control while taking metformin 500 mg b.i.d. In conjunction with continued metformin administration, the patient was given an oral daily nutritional supplement comprising the following ingredients: chromium 333 µg (in the form of chromium picolinate/polynicotinate); magnesium 46 mg (in the form of 384 mg magnesium chloride); vanadyl-sulfate **hydrate** 100 mg; vitamin E 400 IU, and folate 400 µg. In addn. to the lowered HbA1c and fasting blood sugar levels, the patient experienced a significant lowering of total cholesterol and a concomitant lowering of triglyceride, HDL and LDL levels.


IT 122320-73-4, RosiglitazoneRL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (compns. for treatment of glucose metab. disorders)RN 122320-73-4 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met hyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



## L5 ANSWER 12 OF 14 HCPLUS COPYRIGHT 2002 ACS

Full Text	<input type="checkbox"/> Citing References
-----------	--

ACCESSION NUMBER: 1999:404959 HCPLUS

DOCUMENT NUMBER: 131:58818

TITLE: Preparation of a thiazolidinedione derivative as  
hydrate for prophylaxis or treatment of diabetes

INVENTOR(S): Blackler, Paul David James; Lee, David C.; Sasse, Michael John

PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9931095	A1	19990624	WO 1998-EP8155	19981214
------------	----	----------	----------------	----------

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
--

TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314107 AA 19990624 CA 1998-2314107 19981214

AU 9919679 A1 19990705 AU 1999-19679 19981214

EP 1040110 A1 20001004 EP 1998-964510 19981214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 9813600 A 20001010 BR 1998-13600 19981214

JP 2002508373 T2 20020319 JP 2000-539019 19981214

ZA 9811506 A 20001106 ZA 1998-11506 19981215

NO 2000003069 A 20000615 NO 2000-3069 20000615

US 2002137940 A1 20020926 US 2002-82879 20020226

PRIORITY APPLN. INFO.: GB 1997-26566 A 19971216

WO 1998-EP8155 W 19981214

US 2000-581826 B1 20000616

AB Prepn. of a **hydrate** of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleate (I) for prophylaxis and/or treatment of diabetes mellitus and conditions assocd. with it is described. The compd. comprises water in the range of 0.4-2.5% wt./wt. and provides a specific IR spectrum, an X-ray powder diffraction pattern, a Raman spectrum, and/or a solid-state NMR spectrum. I with the water content of 0.54% wt./wt. was prepnd. from 6 g of the I free base and 2.1 g maleic acid salt by heating in MeOH to 55° to obtain a soln.; the soln. was filtered, reheated at 55°, and then cooled to 0-5° and stirred. The product was filtered and dried at 52° in vacuo to give I in 84% yield (6.7 g).

IT 227606-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of thiazolidinedione deriv. as **hydrate** for prophylaxis or treatment of diabetes)

RN 227606-02-2 HCPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1


CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1999:404958 HCAPLUS

DOCUMENT NUMBER: 131:63474

TITLE: **Hydrate of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt**

INVENTOR(S): Blackler, Paul David James; Lee, David C.; Sasse, Michael John

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9931094 A1 19990624 WO 1998-EP8154 19981214

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314965 AA 19990624 CA 1998-2314965 19981214AU 9922723 A1 19990705 AU 1999-22723 19981214BR 9813604 A 20001010 BR 1998-13604 19981214EP 1045847 A1 20001025 EP 1998-966321 19981214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002508372 T2 20020319 JP 2000-539018 19981214ZA 9811505 A 20001106 ZA 1998-11505 19981215TW 467913 B 20011211 TW 1998-87121122 19981216NO 2000003068 A 20000615 NO 2000-3068 20000615US 2002099081 A1 20020725 US 2002-72096 20020207PRIORITY APPLN. INFO.: GB 1997-26568 A 19971216WO 1998-EP8154 W 19981214US 2000-581719 A1 20000616

AB A **hydrate** of the title compd. is prep'd. which is useful in treatment and/or prophylaxis of diabetes mellitus and its complications and assoc'd. conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinemia, obesity, and gestational diabetes, and is particularly suitable for bulk prep'n. and handling. The **hydrate** is characterized by a water content of 0.2-1.1 wt.% and by its IR spectrum and x-ray powder diffraction pattern. The **hydrate** is prep'd. by crystn. from an aq. alkanol, preferably contg. 2.0-2.5 vol.% water.

IT 227606-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(hydrate of antidiabetic thiazolidinedione deriv.)

RN 227606-02-2 HCPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met hyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1


CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2002 ACS

Full Text	<input checked="" type="checkbox"/> Citing References
-----------	---

ACCESSION NUMBER: 1999:404957 HCAPLUS

DOCUMENT NUMBER: 131:49500

TITLE: Substituted thiazolidinedione derivative and its preparation for pharmaceutical use

INVENTOR(S): Lynch, Ian Robert; Choudary, Bernadette Marie; Sasse, Michael John

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9931093 A1 19990624 WO 1998-EP8153 19981214

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314967 AA 19990624 CA 1998-2314967 19981214AU 9922722 A1 19990705 AU 1999-22722 19981214BR 9813598 A 20001010 BR 1998-13598 19981214EP 1042321 A1 20001011 EP 1998-966320 19981214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002508371 T2 20020319 JP 2000-539017 19981214ZA 9811504 A 20000615 ZA 1998-11504 19981215NO 2000003070 A 20000615 NO 2000-3070 20000615US 2002133016 A1 20020919 US 2002-71339 20020208PRIORITY APPLN. INFO.: GB 1997-26563 A 19971216WO 1998-EP8153 W 19981214US 2000-581816 A1 20000616

AB A **hydrate** of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt contg. 0.3-0.6 molar equivs. water is useful for treatment and/or prophylaxis of diabetes mellitus and assocd. conditions and complications. The compd. is characterized by its IR, Raman, and NMR spectra and its x-ray powder diffraction pattern. It is prep'd. by crystg. the anhyd. compd. from aq. EtOH, other aq. solvent mixts., or H<sub>2</sub>O contg. 2-5 vol.% AcOH or other org. acid, and is esp. suitable for bulk prepn. and handling.

IT 227606-02-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(substituted thiazolidinedione deriv. and its prepn. for pharmaceutical use)

RN 227606-02-2 HCAPLUS


CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1


CRN 122320-73-4

CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> **file hcaplus**

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		67.86	208.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	ENTRY	SINCE FILE SESSION	TOTAL
CA SUBSCRIBER PRICE		-8.67	-8.67

FILE 'HCAPLUS' ENTERED AT 14:25:08 ON 04 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Oct 2002 VOL 137 ISS 15  
 FILE LAST UPDATED: 3 Oct 2002 (20021003/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> **d his**

(FILE 'HOME' ENTERED AT 14:21:20 ON 04 OCT 2002)

FILE 'REGISTRY' ENTERED AT 14:21:36 ON 04 OCT 2002  
 L1 STRUCTURE uploaded  
 L2 2 S L1  
 L3 48 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:23:03 ON 04 OCT 2002

L4 490 S L3  
 L5 14 S L4 AND HYDRA?

FILE 'HCAPLUS' ENTERED AT 14:25:08 ON 04 OCT 2002

=> s l5 and hydrochloride  
 103264 HYDROCHLORIDE  
 7153 HYDROCHLORIDES  
 107959 HYDROCHLORIDE  
 (HYDROCHLORIDE OR HYDROCHLORIDES)  
 L6 6 L5 AND HYDROCHLORIDE

=> d l6, ibib abs fhitstr, 1-6

L6 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2002 ACS

Full  Citing  
 Text  References

ACCESSION NUMBER: 2002:637641 HCAPLUS

DOCUMENT NUMBER: 137:169309

TITLE: Preparation of substituted aminobenzene derivatives as  
 glucocorticoid receptor modulators

INVENTOR(S): Link, James T.; Sorensen, Bryan K.; Patel, Jyoti R.;  
 Arendsen, David L.; Li, Gaoquan

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 272 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

<u>WO 2002064550</u>	A1	20020822	<u>WO 2002-US4501</u>	20020212
----------------------	----	----------	-----------------------	----------


W: CA, JP, MX

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, TR

PRIORITY APPLN. INFO.: US 2001-783636 A 20010214

OTHER SOURCE(S): MARPAT 137:169309

GI



AB Gen, hydroxyalkyl, substituted amine; R4 is substituted aminobenzenes I were prep'd. and are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal, wherein R1-R3 are each independently hydrogen, alkoxy carbonyl, alkoxy, alkoxyalkyl, alkyl, alkyl carbonyl, carboxy, halogen, hydroxyalkyl, substituted amine; R4 is hydrogen, alkenyl, alkoxy, alkoxyalkenyl, alkoxyalkoxy, alkoxyalkyl, alkoxyalkynyl, alkoxy carbonyl, alkoxy carbonylalkoxy, alkoxy carbonylalkenyl, alkoxy carbonylalkyl, alkoxy carbonylalkynyl, alkyl, alkyl carbonyl, alkyl carbonylalkenyl, alkyl carbonylalkoxy, alkyl carbonylalkyl, alkyl carbonylalkynyl, alkynyl, carboxy, carboxyalkenyl, carboxyalkyl, carboxyalkynyl, haloalkoxy, haloalkyl, haloalkenyl, haloalkynyl, halogen, hydroxyalkyl, substituted amine; R5 is hydrogen, alkyl; R6 is hydrogen, alkoxy carbonyl, alkoxy sulfonyl, alkyl, alkyl carbonyl, alkyl sulfonyl, aryl alkoxy carbonyl, aryl alkyl carbonyl, aryl alkyl sulfonyl, aryl carbonyl, aryl sulfonyl, cycloalkyl carbonyl, cycloalkyl alkyl carbonyl, cycloalkyl sulfonyl, cycloalkyl alkyl sulfonyl, heterocycle carbonyl, heterocycle alkyl carbonyl, heterocycle sulfonyl, heterocycle alkyl sulfonyl, amide, aminosulfonyl; X and Y are independently heteroatom-contg. hydrocarbon. Thus, N-[3-(dibenzylamino)-2-methylphenyl]ethanesulfonamide was prep'd. as glucocorticoid receptor modulator. A method of treating symptoms related to type II diabetes wherein said symptoms are selected from the group consisting of hyperglycemia, hyperinsulinemia, inadequate, glucose clearance, obesity, hypertension and high glucocorticoid levels in a mammal comprising administering a therapeutically effective amt. of a compd. of title compds. A method of treating diseases assoc'd. with an excess or deficiency of glucocorticoids, said diseases selected from the group consisting of diabetes, obesity, Syndrome X, Cushing's Syndrome, Addison's disease, inflammatory diseases such as asthma, rhinitis and arthritis, allergy, autoimmune disease, immunodeficiency, anorexia, cachexia, bone loss or bone frailty, and wound healing comprising administering a therapeutically effective amt. of a compd. of title compds.


IT 122320-73-4, Rosiglitazone

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. of substituted aminobenzene derivs. as glucocorticoid receptor modulators)


RN 122320-73-4 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2002 ACS

Full Text  Citing References

ACCESSION NUMBER: 2001:780683 HCAPLUS

DOCUMENT NUMBER: 135:335156

TITLE: Modified-release formulations containing a hypnotic agent

INVENTOR(S): Platteeuw, Johannes Jan; Van Den Heuvel, Dennie Johan Marijn; Van Dalen, Frans; Lemmens, Jacques Maria

PATENT ASSIGNEE(S): Synthon B.V., Neth.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

<u>WO 2001078725</u>	A2	20011025	<u>WO 2001-NL299</u>	20010412
----------------------	----	----------	----------------------	----------

<u>WO 2001078725</u>	A3	20011220
----------------------	----	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-196939P P 20000413

AB Hypnotic pharmaceutical compns. are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably spherical and exhibit a dissoln. profile that includes 60% of the hypnotic agent being released from the pellet not earlier than 5 min from the start of a specified in vitro dissoln. test. Although the modified release profile can include 50 of the hypnotic agent being released not earlier than 15 min after the start of the dissoln. test, the pellet preferably does not contain a release rate controlling excipient or coating. Instead, microcryst. cellulose and the active constitute the majority of the pellet, e.g. 90 or more. Spherical pellets are also made by a convenient method that is applicable to any pharmaceutically active agent. Microcryst. cellulose 1703, zolpidem **hydrochloride hydrate** 189.2 g, and water 1892 mL were mixed and stirred for 15 min. Water was then removed and the resulted pellets were dried and fractionated by sieving.


IT 122320-73-4, Rosiglitazone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified-release formulations contg. hypnotic agent)


RN 122320-73-4 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met hyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



## L6 ANSWER 3 OF 6 HCPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2001:693320 HCPLUS

DOCUMENT NUMBER: 135:247196

TITLE: Preparation of non-hygroscopic **hydrochloride** salts  
of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

INVENTOR(S): Craig, Andrew Simon

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001068646	A1	20010920	WO 2001-GB1131	20010314
---------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-6133 A 20000314

AB A substantially non-hydrated and non-hygroscopic or slightly hygroscopic **hydrochloride** salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (I); a pharmaceutical compn. contg. such a compd., a process of prep. such a compd. and the use of such a compd. in medicine is disclosed. I was prep'd. by the reaction of HCl with the base, m.p. = 167-170. I was non-hygroscopic.

IT 302543-62-0P


RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of non-hygroscopic **hydrochloride** salts of  
pyridylaminoethoxybenzyl thiazolidinedione)RN 302543-62-0 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



# HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 HCPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2001:338762 HCPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

<u>WO 2001032928</u>	A2	20010510	<u>WO 2000-US30474</u>	20001103
----------------------	----	----------	------------------------	----------

<u>WO 2001032928</u>	A3	20020725
----------------------	----	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105  
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

IT 122320-73-4, Rosiglitazone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)


RN 122320-73-4 HCPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methylyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



## L6 ANSWER 5 OF 6 HCPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2001:283949 HCPLUS

DOCUMENT NUMBER: 134:311218

TITLE: Synthesis and use of heterocyclic sodium/proton exchange inhibitors

INVENTOR(S): Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001027107	A2	20010419	WO 2000-US27461	20001002
---------------	----	----------	-----------------	----------

WO 2001027107	A3	20020124
---------------	----	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1224183 A2 20020724 EP 2000-968723 20001002


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

NO 2002001717 A 20020610 NO 2002-1717 20020411

PRIORITY APPLN. INFO.: US 1999-158755P P 19991012  
WO 2000-US27461 W 20001002

OTHER SOURCE(S): MARPAT 134:311218

GI



AB Compds. of formula I [wherein; n is 1-5; X is N or CR5, where R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R1 is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R2, R3 and R4 are any of the groups set out for R1 and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R1 is preferably aryl or heteroaryl] are claimed.

Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butyldiethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding  $\alpha$ -chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents,  $\beta$ -adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

IT 122320-73-4, Rosiglitazone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceuticals also contg.; synthesis and use of heterocyclic sodium/proton exchange inhibitors)


RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2002 ACS

Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 2000:756704 HCAPLUS

DOCUMENT NUMBER: 133:325652

TITLE: 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride monohydrate pharmaceutical

INVENTOR(S): Blackler, Paul David James; Craig, Andrew Simon; Giles, Robert Gordon; Sasse, Michael John

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2000063206 A2 20001026 WO 2000-GB1527 20000419

WO 2000063206 A3 20010222

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1173437 A2 20020123 EP 2000-920895 20000419

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO


BR 2000009898 A 20020416 BR 2000-9898 20000419

NO 2001005105 A 20011219 NO 2001-5105 20011019

PRIORITY APPLN. INFO.: GB 1999-9075 A 19990420

WO 2000-GB1527 W 20000419

GI



AB 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

**hydrochloride monohydrate** (I.HCl.H<sub>2</sub>O) is characterized in that it: (i) provides an IR spectrum contg. peaks at 3358, 2764, 1245, 833 and 760 cm<sup>-1</sup>; and/or (ii) provides an XRPD pattern contg. peaks at 15.0, 17.7, 23.0, 30.0 and 31.4 >2303082-83-9P


RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione **hydrochloride monohydrate pharmaceutical**)


RN 303082-83-9 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monohydrochloride, monohydrate (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



# HCl

# H<sub>2</sub>O

=&gt; file caold

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		32.75	241.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	ENTRY	SINCE FILE SESSION	TOTAL
CA SUBSCRIBER PRICE		-3.72	-12.39

FILE 'CAOLD' ENTERED AT 14:27:13 ON 04 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> **d his**

(FILE 'HOME' ENTERED AT 14:21:20 ON 04 OCT 2002)

FILE 'REGISTRY' ENTERED AT 14:21:36 ON 04 OCT 2002

L1       STRUCTURE UPLOADED

L2       2 S L1

L3       48 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 14:23:03 ON 04 OCT 2002

L4       490 S L3

L5       14 S L4 AND HYDRA?

FILE 'HCAPLUS' ENTERED AT 14:25:08 ON 04 OCT 2002



L6       6 S L5 AND HYDROCHLORIDE

FILE 'CAOLD' ENTERED AT 14:27:13 ON 04 OCT 2002

=> **s l3**

L7       0 L3

=>



chain nodes :  
 7 10 11 12 14 23 24 30 31

ring nodes :  
 1 2 3 4 5 6 15 16 17 18 19 20 25 26 27 28 29

chain bonds :  
 7-10 7-11 11-12 12-14 14-17 20-23 23-24 24-27 25-31 28-30

ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20 25-26 25-29  
 26-27 27-28 28-29

exact/norm bonds :  
 7-10 12-14 14-17 25-29 25-31 28-29 28-30

exact bonds :  
 7-11 11-12 20-23 23-24 24-27 25-26 26-27 27-28

normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20

isolated ring systems :  
 containing 1 : 15 : 25 :

G1:CH3,Et

G2:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS  
 12:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 23:CLASS  
 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS 31:CLASS